secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001641172-25-013803
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA reports 17.8-month median OS in NSCLC trial; new partial response after 20 months
--------------------------------------------------------------------------------

- Median overall survival of 17.8 months for 22 third-line NSCLC patients, nearly triple the 5-6 month SOC.
- 95% CI lower bound of 12.5 months and 99% CI lower bound of 10.8 months shown.
- New partial response (>=30% tumor reduction) observed after >20 months on treatment.
- Longest-surviving patient reached 24.3 months and completed 32 cycles of therapy.
- Potential FDA decision for ateganosine as early as next year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225013803/0001641172-25-013803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225013803/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer